# Clinical Trials Data KRAS - Document 39

# COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01596790

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Age \\> 18 years\n\* Colon or rectum adenocarcinoma (based on the histology)\n\* Visceral metastases (synchronous and/or metachronous)\n\* Metastatic disease measurable with the RECIST 1.1 criteria\n\* WHO performance status 0, 1 or 2\n\* Life expectancy\\>3 months when starting the treatment\n\* Chemotherapy in metastatic 1rst line combining a protocol of conventional chemotherapy combining 5-FU and IRINOTECAN (FOLFIRI, XELIRI) associated with bevacizumab\n\* Follow-up of at least one year\n\* Collection of the written consent\n\* Social security affiliation\n\nExclusion Criteria:\n\n\* 2nd line chemotherapy and beyond\n\* History of other cancers considered not cured\n\* Active and progressive infection or other serious disease that may not allow the patient to receive the treatment\n\* refusal to participate\n\* Patient unable to express his consent\n\* Pregnant women\n\* Patient unable to be followed-up for at least one year\n\* Current participation to another clinical trial\n\* Patients under guardianship\n\* Vulnerable people protected by the law",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
The provided eligibility criteria \*\*do not mention KRAS mutation status\*\*. Therefore, having a KRAS mutation would \*not\* automatically exclude a patient from this trial. They could still be eligible if they meet all other inclusion criteria and none of the exclusion criteria.